Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation
Filip Jankú(The University of Texas MD Anderson Cancer Center), Alex A. Adjei(Cleveland Clinic), Debora Schmitz(PIQUR Therapeutics (Switzerland)), Afshin Dowlati(University Hospitals of Cleveland), Sarah P. Blagden(Churchill Hospital), Faye M. Johnson(The University of Texas MD Anderson Cancer Center), Mateusz Opyrchal(Indiana University Health), Martin Forester(University College London), Cinta Hierro(Vall d'Hebron Hospital Universitari), Andreas Wicki(University Hospital of Basel)
Cited by 7
Related Papers
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
|Blood|2016|1.6k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals
|Annals of the American Thoracic Society|2018|723
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
|Journal of Clinical Oncology|1999|697
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|459